Send a text

🧠 Clinical Context

DOACs (Direct Oral Anticoagulants) have revolutionized anticoagulation—goodbye routine INRs, hello convenience. But while they’ve made our lives easier, they’re not always a fit for every scenario. Here's how to navigate the DOAC jungle.

✅ When DOACs Are Preferred

• Venous Thromboembolism (VTE)
• Atrial Fibrillation
  • ⚠️ Exclude patients with:
    • Mechanical heart valves
    • Rheumatic mitral valve disease
       (That’s why cardiologists note “non-rheumatic” AF in their documentation—treatment plan hinges on it.)

⛔ When DOACs Are a No-Go

• Mechanical Heart Valves → Warfarin only
• Rheumatic AF → Warfarin still rules
• Thrombotic Antiphospholipid Syndrome → Warfarin
• Transcatheter Aortic Valve Replacement (TAVR) → Antiplatelet therapy
• Embolic Stroke of Undetermined Source → Antiplatelets preferred

🤔 The Gray Zone: Uncertain Use Cases

These aren’t absolute yes or no. Instead, cue shared decision-making and expert input:

• Pregnancy
  • No strong evidence yet; avoid unless discussed with OB and hematology.
• End-Stage Renal Disease (ESRD)
  • Initially excluded from DOAC trials.
  • Some are doing well, but still a case-by-case basis.
• Others That Require Discussion:
  • Left Ventricular Thrombus
  • Catheter-Associated DVT
  • Splanchnic Vein Thrombosis
  • Cerebral Venous Thrombosis

🧩 Clinical Takeaway

DOACs are game-changers—but they’re not plug-and-play for everyone. For classic AF and VTE? Go for it. For valves, rheumatic disease, or complex syndromes? Tread carefully. And when in doubt, involve the patient in the decision.

🎯 Bottom line: Not every clot deserves a DOAC—some still want warfarin or a platelet plan.

Let me know when you're ready for the next one!